Alternate-Day Buprenorphine Administration. Phase IV - 5

NCT00000223 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Opioid-Related Disorders

Interventions

DRUG: Buprenorphine

Sponsor

National Institute on Drug Abuse (NIDA)

Collaborators

[object Object]